Literature DB >> 14983217

The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors.

Ann Gils1, Paul J Declerck.   

Abstract

Plasminogen activator inhibitor-I (PAI-I) is an important component of the plasminogen/plasmin system as it is the main inhibitor of tissue-type and urokinase-type plasminogen activator. Consequently, PAI-I plays an important role in cardiovascular diseases (mainly through inhibition of t-PA), and in cell migration and tumor development (mainly through inhibition of u-PA and interaction with vitronectin). As a member of the serpin superfamily, PAI-I shares important structural properties with other serpins. However, PAI-I also exhibits unique conformational and functional properties. The current review provides an overview of the knowledge on PAI-I gathered since its discovery two decades ago. We discuss (a) its structural properties of the protein and their subsequent relation to functional activities, (b) its role in a wide variety of (patho)physiological processes and (c) a number of strategies to interfere with its functional properties eventually aiming at pharmacological modulation of this risk factor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14983217     DOI: 10.1160/TH03-12-0764

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  22 in total

1.  High-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling.

Authors:  Jan K Jensen; Peter G W Gettins
Journal:  Protein Sci       Date:  2008-08-25       Impact factor: 6.725

Review 2.  Enhanced spontaneous thrombolysis: a new therapeutic challenge.

Authors:  I B Kovacs; D A Gorog; J Yamamoto
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

3.  Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability.

Authors:  Jan K Jensen; Lawrence C Thompson; Joel C Bucci; Poul Nissen; Peter G W Gettins; Cynthia B Peterson; Peter A Andreasen; J Preben Morth
Journal:  J Biol Chem       Date:  2011-06-21       Impact factor: 5.157

4.  Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities.

Authors:  David F Moore; Oleg V Krokhin; Ronald C Beavis; Markus Ries; Chevalia Robinson; Ehud Goldin; Roscoe O Brady; John A Wilkins; Raphael Schiffmann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-14       Impact factor: 11.205

Review 5.  Serine proteases, inhibitors and receptors in renal fibrosis.

Authors:  Allison A Eddy
Journal:  Thromb Haemost       Date:  2009-04       Impact factor: 5.249

Review 6.  Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis.

Authors:  Rui-Ming Liu
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

7.  Serum vitamin C levels modulate the lifespan and endoplasmic reticulum stress response pathways in mice synthesizing a nonfunctional mutant WRN protein.

Authors:  Lucie Aumailley; Marie Julie Dubois; Tracy A Brennan; Chantal Garand; Eric R Paquet; Robert J Pignolo; André Marette; Michel Lebel
Journal:  FASEB J       Date:  2018-02-08       Impact factor: 5.191

8.  Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular Disease.

Authors:  Tessa M Simone; Paul J Higgins
Journal:  Mol Med Ther       Date:  2012-08-05

9.  Megsin gene: its genomic analysis, pathobiological functions, and therapeutic perspectives.

Authors:  Toshio Miyata; Ming Li; Xueqing Yu; Noriaki Hirayama
Journal:  Curr Genomics       Date:  2007-05       Impact factor: 2.236

10.  Toxicogenomic analysis of mainstream tobacco smoke-exposed mice reveals repression of plasminogen activator inhibitor-1 gene in heart.

Authors:  Sabina Halappanavar; Martin R Stampfli; Lynn Berndt-Weis; Andrew Williams; George R Douglas; Carole L Yauk
Journal:  Inhal Toxicol       Date:  2009-01       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.